Study to Examine the Cytokine Levels, Gene Expression and Safety of a Single Nasal Dose of JNJ-43260295, in Healthy Participants, and Atopic Participants With Mild to Mild-Persistent Asthma

Inclusion Criteria

• •A. Healthy Participants and Atopic Mild to Mild-Persistent Asthmatic Participants:
• •Participants must be non-smokers or non-regular smokers (1 to 2 cigarettes on the weekend as part of social gathering) for at least 3 months prior to Screening, according to the participant's self-reported medical history. Participants should be willing to (continue to) abstain from smoking from Screening until completion of the last study related activity
• •Participants must have a body mass index (BMI: weight in kilogram \[kg\] divided by the height in square meter \[m\^2\]) of 18.0 to 30.0 kg/m\^2, extremes included
• •Participants must have a normal 12-lead electrocardiogram (ECG) at Screening including normal sinus rhythm (heart rate between 40 and 100 beats per minute \[bpm\]); QT interval corrected for heart rate according to Fridericia (QTcF) interval less than and equal to (\<=) 450 milliseconds (ms); QRS interval lower than 120 ms; and PR interval \<=220 ms
• •Participants must be healthy, with the exception of findings related to asthma and allergy in atopic mild to mild-Persistent asthmatic participants, on the basis of a medical evaluation that reveals the absence of any clinically relevant abnormality and includes a physical examination, medical history, vital signs (Systolic Blood Pressure \[BP\], Diastolic BP, pulse rate, respiratory rate, and body temperature), and the results of blood biochemistry and hematology tests performed at Screening
• •Participants must be willing/ able to adhere to the prohibitions and restrictions specified in the protocol and study procedures
• •B. Atopic Mild to Mild-Persistent Asthmatic Participants:
• •Participants with Investigator-diagnosed mild to mild-persistent asthma based on the Guidelines for the Diagnosis and Management of Asthma
• •Participants having a well-established allergen profile (participants have been previously skin tested and, by history, have allergic responses to specific allergens)
• •Participants with forced expiratory volume in 1 second (FEV1) greater than (\>) 70 percent (%) of predicted at Baseline